BioSpace News Archive

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGWO) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has been issued a patent from the Canadian Intellectual Property Office (“CIPO”), No. 3101853, for the treatment of interstitial lung disease with NP-120 (“Ifenprodil”).

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced that it has entered into a securities purchase agreement with certain institutional investors to purchase 2,500,000 shares of Series A convertible redeemable preferred stock and 500,000 shares of Series B convertible redeemable preferred stock.

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the election of Kenneth M. Ferguson, Ph.D., to its Board of Directors.

Bio-Techne Corporation (NASDAQ:TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, today announced it has reached an agreement to acquire Namocell, Inc.

Study will measure immune responses generated by M2SR and high dose vaccine separately and in combination in the highly vulnerable 65-85 years old population.

SIRTLab Corporation, a pioneer in the manipulation of sirtuin proteins for the treatment of severe liver diseases and longevity, today announced the appointment of Michael G. Kauffman , MD, PhD, as Co-Chairman of the Board of Directors and Chief Medical Officer (CMO).

Numinus Wellness Inc. today announced that its subsidiary Numinus Bioscience Inc. (“Numinus Bioscience”) has filed a patent application to the World Intellectual Property Organization (WIPO), an agency of the United Nations, for a rapid production process for Psilocybe and other fungi species containing psilocybin and other compounds.

Alpha Cognition Inc. today announced positive results from its pivotal bioequivalence study with ALPHA-1062, a proprietary, delayed release oral tablet formulation in development for the treatment of mild to moderate Alzheimer’s Disease (AD).

New data from pooled analysis shows DecisionDx ® -Melanoma can identify patients at a high risk of melanoma recurrence within a patient population deemed low risk ( T1, ≤1mm) by traditional staging systems.

IMV achieves predetermined milestone to access the remaining $US10 Million under its Debt Facility with Horizon.